Olmesartan Medoxomil - CAS 144689-63-4
Catalog number:
144689-63-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H30N6O6
Molecular Weight:
558.59
COA:
Inquire
Targets:
Angiotensin Receptor
Description:
Olmesartan Medoxomil is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype angiotensin II receptor antagonist.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CS-866
MSDS:
Inquire
1. Olmesartan Medoxomil A Review of its Use in the Management of Hypertension
Lesley J. Scott and Paul L. McCormack. Drugs 2008; 68 (9): 1239-1272
Studies in monkeys and rabbits suggest that olmesartan medoxomil may inhibit or reverse the ents formation of atherosclerotic lesions (table II). Although olmesartan medoxomil and atenolol reduced carotid intima media thickness (a surrogate marker of atherosclerotic plaque formation) to a similar extent in hypertensive patients with atherosclerosis, olmesartan medoxomil, but not atenolol, reduced the volume of large plaques, indicating a potential anti-atheroslcerotic effect independent of BP lowering.
2. Olmesartan Medoxomil/Amlodipine
Mark Sanford and Susan J. Keam. Drugs 2009; 69 (6): 717-729
Olmesartan medoxomil/amlodipine (Sevikar®), a fixed-dose formulation of the angiotensin II type 1 (AT1) receptor blocker olmesartan medoxomil and the dihydropyridine CCB amlodipine, is approved in several European countries for once-daily administration in patients with essential hypertension who have not responded adequately to monotherapy with olmesartan medoxomil or amlodipine, or who are receiving separate tablets as combination therapy. In the US, the fixed-dose formulation is marketed as AzorTM and is approved for the treatment of hypertension, alone or with other antihypertensive agents. This article focuses, from an EU perspective, on efficacy and tolerability studies of olmesartan medoxomil/amlodipine in patients with hypertension, with a brief overview of its pharmacological properties. Medical literature on the use of olmesartan medoxomil/amlodipine in hypertension was identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health j Adis). Additional references were identified fromthe reference lists of published articles.
3. Efficacy and Tolerability of Olmesartan Medoxomil Combined with Amlodipine in Patients with Moderate to Severe Hypertension after Amlodipine Monotherapy
A Randomized, Double-Blind, Parallel-Group, Multicentre Study. Clin Drug Invest 2009; 29 (1): 11-25
Olmesartan medoxomil/amlodipine 40/5 mg produced the most rapid lowering of SBP and DBP. A difference in mean SeSBP reduction of 1.4 mmHg was evident between the olmesartan medoxomil/amlodipine 40/5 mg group and the olmesartan medoxomil/amlodipine 20/5 mg group at week 16, although the magnitude of SeDBP reduction was similar in these groups at week 16 (–9.6 mmHg and–9.5 mmHg, respectively). Significantly higher proportions of patients reached the BP goal with olmesartan medoxomil/ amlodipine 5 mg combination regimens compared with the placebo/amlodipine 5 mg regimen. At the end of 8 weeks of double-blind therapy (week 16), 51% and 54% of patients treated with olmesartan medoxomil/amlodipine 40/5 mg and olmesartan medoxomil/amlodipine 20/5 mg, respectively, reached BP goal (p < 0.0001 vs 30% [55/184] of patients at goal treated with placebo/amlodipine 5 mg). Thirty-nine percent of patients treated with olmesartan medoxomil/amlodipine 10/5 mg reached BP goal (p = 0.0286 vs placebo/amlodipine 5 mg).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Angiotensin Receptor Products


CAS 114798-26-4 Losartan

Losartan
(CAS: 114798-26-4)

Losartan, an antagonist of angiotensin II receptor, could be effective in the treatment of hypertensive. IC50: 20nM.

CAS 159432-28-7 A 779

A 779
(CAS: 159432-28-7)

A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor) (IC50= 0.3 nM) with no significant affinity for AT1 or AT2 receptors at a concentrat...

CAS 247257-48-3 Fimasartan

Fimasartan
(CAS: 247257-48-3)

Fimasartan, also called as BR-A657, approved for the treatment of mild to moderate hypertension in South Korea, is a novel, non-peptide angiotensin II (Ang II) ...

CAS 145040-37-5 Candesartan Cilexetil

Candesartan Cilexetil
(CAS: 145040-37-5)

Candesartan blocks the effects of angiotensin II at the angiotensin II type 1 (AT1) receptor. Candesartan cilexetil is a prodrug that is activated to candesarta...

CAS 863031-24-7 Azilsartan medoxomil monopotassium

Azilsartan medoxomil monopotassium
(CAS: 863031-24-7)

Azilsartan medoxomil monopotassium is an azilsartan prodrug and and an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM. It is...

CAS 145733-36-4 Tasosartan

Tasosartan
(CAS: 145733-36-4)

Tasosartan, a pyrido-pyrimidin derivative, has been found to be an angiotensin II receptor antagonist that could have probable effect against hypertension. It h...

CAS 936623-90-4 LCZ696

LCZ696
(CAS: 936623-90-4)

LCZ696 is a potent ARNi inhibitor and an investigational drug to treat heart failure. Chemically, LCZ696 is a mixture of valsartan and sacubitril in a 1:1 mol...

CAS 139481-59-7 Candesartan

Candesartan
(CAS: 139481-59-7)

Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model

Sparsentan
(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

CAS 133085-33-3 BIBS 39

BIBS 39
(CAS: 133085-33-3)

BIBS 39, a nonpeptide angiotensin II receptor antagonist, has been found to exhibit potential antihypertensive activity in rat. It has been already discontinued...

CAS 141887-34-5 A81988

A81988
(CAS: 141887-34-5)

A81988 is a potent, orally active angiotensin I1 antagonist with a long duration of action whose pharmacological profile has established it as an important tool...

CAS 51833-78-4 Angiotensin I/II (1-7)

Angiotensin I/II (1-7)
(CAS: 51833-78-4)

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor, inducing vasorelaxation through release of NO and prostaglandins.

CAS 127060-75-7 CGP-42112A

CGP-42112A
(CAS: 127060-75-7)

CGP-42112A, an angiotensin AT2 receptor agonist which could probably lead to the inhibition of ATPase and contraction of aortic rings in rabbit.

AVE 0991
(CAS: 304462-19-9)

AVE 0991 is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.

Tranilast Sodium
(CAS: 104931-56-8)

Tranilast, an allergic media blocker, is effective for the treatment of asthma and is also used to treat asthma, allergic rhinitis and other allergic disorders.

BMS 183920
(CAS: 153072-33-4)

BMS 183920, a quinoline derivative, has been found to be an angiotensin II receptor antagonist that could have potential usage in antihypertensive study.

CAS 863031-21-4 Azilsartan Medoxomil

Azilsartan Medoxomil
(CAS: 863031-21-4)

Azilsartan Medoxomil is a potent angiotensin II type 1 (AT1) receptor antagonist that inhibits the RAAS, with an IC50 of 2.6 nM. It exhibits more than 10,000-fo...

MK 996
(CAS: 157263-00-8)

MK-996, an imidazopyridine derivative, has been found to be an angiotensin receptor antagonist that was once developed in the treatment of hypertension by Merck...

CAS 138402-11-6 Irbesartan

Irbesartan
(CAS: 138402-11-6)

Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.

CAS 159748-08-0 LY285434

LY285434
(CAS: 159748-08-0)

An antagonist of angiotensin II receptor

Chemical Structure

CAS 144689-63-4 Olmesartan Medoxomil

Quick Inquiry

Verification code

Featured Items